A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.-Reference-Cited by-同舟云学术

A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:2598-2598
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Bauer Todd Michael¹,Infante Jeffrey R.²,Eder Joseph Paul³,LoRusso Patricia⁴,LaVallee Theresa⁵,Gedrich Rich⁵,Sidor Carolyn⁵,Falchook Gerald Steven⁶

Affiliation:

1. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

2. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

3. Yale Cancer Center, Yale School of Medicine, New Haven, CT

4. Yale Cancer Center, New Haven, CT

5. Kolltan Pharmaceuticals, New Haven, CT

6. Sarah Cannon Research Institute At HealthONE, Denver, CO

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.2598

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER Receptor, Current, and Emerging Therapeutic Targets;Handbook of Cancer and Immunology;2023

2. A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors;The Oncologist;2021-07-21

3. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress;Cancer Treatment Reviews;2018-07

4. HER3 as a Therapeutic Target in Cancer;BioDrugs;2016-12-20

5. HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy;Recent Patents on Anti-Cancer Drug Discovery;2016-08-09